Suppr超能文献

相似文献

1
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7. doi: 10.1073/pnas.0507360102. Epub 2005 Nov 3.
2
Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
J Neurosci Res. 2009 May 1;87(6):1283-95. doi: 10.1002/jnr.21949.
5
Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
Hum Mol Genet. 2007 Sep 1;16(17):2031-9. doi: 10.1093/hmg/ddm151. Epub 2007 Jun 20.
6
LRRK2 in Parkinson's disease: protein domains and functional insights.
Trends Neurosci. 2006 May;29(5):286-93. doi: 10.1016/j.tins.2006.03.006. Epub 2006 Apr 17.
8
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
J Neurochem. 2007 Oct;103(1):238-47. doi: 10.1111/j.1471-4159.2007.04743.x. Epub 2007 Jul 10.
10
The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
Biochem Biophys Res Commun. 2009 Nov 20;389(3):449-54. doi: 10.1016/j.bbrc.2009.08.163. Epub 2009 Sep 3.

引用本文的文献

2
Tau uptake by human neurons depends on receptor LRP1 and kinase LRRK2.
EMBO J. 2025 Aug 11. doi: 10.1038/s44318-025-00514-0.
3
14-3-3 binding maintains the Parkinson's associated kinase LRRK2 in an inactive state.
Nat Commun. 2025 Aug 5;16(1):7226. doi: 10.1038/s41467-025-62337-1.
4
Engineering a cell-based orthogonal ubiquitin transfer cascade for profiling the substrates of RBR E3 Parkin.
iScience. 2025 Jun 17;28(7):112913. doi: 10.1016/j.isci.2025.112913. eCollection 2025 Jul 18.
6
Accumulation of LRRK2-associated phospho-Rab12 degenerative lysosomes in tauopathies.
bioRxiv. 2025 Jun 9:2025.06.06.658328. doi: 10.1101/2025.06.06.658328.
7
Recent advances in targeting LRRK2 for Parkinson's disease treatment.
J Transl Med. 2025 Jul 8;23(1):754. doi: 10.1186/s12967-025-06354-0.
8
Role of LRRK2 in axonal transport and Parkinson's disease.
Biochem J. 2025 Jun 25;482(13):BCJ20253133. doi: 10.1042/BCJ20253133.
9
Structural biology of Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2).
J Biol Chem. 2025 Jun 14;301(8):110376. doi: 10.1016/j.jbc.2025.110376.
10
Type II kinase inhibitors that target Parkinson's disease-associated LRRK2.
Sci Adv. 2025 Jun 6;11(23):eadt2050. doi: 10.1126/sciadv.adt2050. Epub 2025 Jun 4.

本文引用的文献

1
A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations.
Neurology. 2005 Sep 13;65(5):741-4. doi: 10.1212/01.wnl.0000172630.22804.73.
2
LRRK2 mutations in Parkinson disease.
Neurology. 2005 Sep 13;65(5):738-40. doi: 10.1212/01.wnl.0000169023.51764.b0.
3
Molecular pathophysiology of Parkinson's disease.
Annu Rev Neurosci. 2005;28:57-87. doi: 10.1146/annurev.neuro.28.061604.135718.
4
Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis.
Hum Mol Genet. 2005 Jul 15;14(14):2063-73. doi: 10.1093/hmg/ddi211. Epub 2005 Jun 8.
6
A common LRRK2 mutation in idiopathic Parkinson's disease.
Lancet. 2005;365(9457):415-6. doi: 10.1016/S0140-6736(05)17830-1.
7
A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.
Lancet. 2005;365(9457):412-5. doi: 10.1016/S0140-6736(05)17829-5.
8
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.
Lancet. 2005;365(9457):410-2. doi: 10.1016/S0140-6736(05)17828-3.
9
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
Neuron. 2004 Nov 18;44(4):601-7. doi: 10.1016/j.neuron.2004.11.005.
10
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.
Neuron. 2004 Nov 18;44(4):595-600. doi: 10.1016/j.neuron.2004.10.023.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验